21 results
A Controlled Trial of Erenumab for Episodic Migraine #EBM #Neuro #Erenumab #Migraine #CGRP #VisualAbstract #NEJM
Episodic Migraine #EBM ... #Neuro #Erenumab ... VisualAbstract #NEJM
PCI in Acute MI with Cardiogenic Shock. #EBM #Cardiology #CULPRITSHOCK #PCI #VisualAbstract #NEJM
PCI in Acute MI ... #EBM #Cardiology ... #CULPRITSHOCK #PCI ... VisualAbstract #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Osimertinib #NSCLC ... #Survival #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM
Rate of Survival and the Risk of Death at 90 Days, According to Subgroup #EBM #PCC
According to Subgroup #EBM ... #PCC #ADRENAL # ... #SepticShock #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM
Six Trials of Patent Foramen Ovale Closure for Stroke with Results Published in the Journal. #EBM
#EBM #Neuro #Cardiology ... EvidenceSummary #Table #NEJM